• What Is 21 CFR 820?
• What Is 21 CFR 820.120 Device Labeling?
• Key Requirements of 21 CFR 820.120
• 1. Label Approval and Inspection
• 2. Label Integrity and Legibility
• 3. Label Storage and Segregation
• 4. Labeling Operations Controls
• 5. Control Numbers and Traceability
• 21 CFR 820.120 and Device History Records (DHR)
• Common FDA Observations Related to 21 CFR 820 Labeling
• How 21 CFR 820.120 Relates to UDI and Modern Labeling
• Building a Compliant 21 CFR 820.120 Labeling Process
• How This Fits Within FDA Medical Device Labeling Requirements
• How GMP Labeling Supports 21 CFR 820 Compliance

21 CFR Part 820 establishes the FDA’s Quality System Regulation (QSR) for medical device manufacturers. It defines the quality management framework companies must follow to ensure devices are consistently produced and controlled in accordance with regulatory requirements.

The regulation addresses design controls, production and process controls, corrective and preventive action, document control, complaint handling, and recordkeeping. Its purpose is to ensure that finished medical devices are safe, effective, and properly manufactured.

Labeling is included within this quality system framework because labeling errors can directly affect patient safety, product identification, and recall effectiveness. A device that is manufactured correctly but mislabeled may be considered misbranded under federal law. For that reason, FDA dedicates Section 820.120 specifically to labeling control requirements.

It is important to distinguish Part 820 from 21 CFR Part 801. Part 801 governs the content of medical device labels, including required statements and adequate directions for use. Part 820, by contrast, governs how labeling is managed operationally within the quality system.

In practical terms, Part 801 addresses what must appear on a label, while Part 820 addresses how labeling is controlled to prevent errors.

For a more detailed overview, see our supporting resource on Understanding 21 CFR Part 801 Labeling Requirements.

21 CFR 820.120 requires manufacturers to establish and maintain procedures to control labeling activities. The regulation is designed to prevent mix-ups, use of obsolete labels, misapplication, and loss of traceability.

FDA considers labeling controls a high-risk compliance area because labeling errors can lead to incorrect device identification, improper use, or ineffective recalls. As a result, the regulation requires structured procedures governing labeling approval, storage, issuance, inspection, and documentation.

Section 820.120 applies to labels, labeling materials, and labeling operations throughout the manufacturing process. It also intersects with other quality system requirements, including Device History Records and document controls.

Compliance is not achieved by having accurate label artwork alone. It requires procedural discipline and documentation demonstrating that labeling is controlled at every stage of production.

Labeling must remain legible and properly affixed throughout manufacturing, storage, distribution, and expected use conditions. FDA expects manufacturers to evaluate whether labels can withstand real-world environmental stresses.

This may include exposure to sterilization methods, moisture, temperature fluctuations, chemical agents, abrasion, or transportation handling. If labels degrade or detach, critical information such as lot numbers, expiration dates, or usage instructions may become unreadable.

For devices that incorporate barcodes or Unique Device Identifiers, scannability must also be preserved. Legibility failures can compromise traceability systems and hinder recall effectiveness.

Demonstrating compliance often requires validation of label materials, adhesives, and printing methods under anticipated use conditions.

Label storage must be controlled to prevent mix-ups and unauthorized access. Procedures should clearly define how labels are received, stored, accessed, and issued for production.

Obsolete labels must be removed promptly from manufacturing areas to prevent accidental application. Environmental controls may also be necessary to protect label stock from damage prior to use.

FDA expects manufacturers to demonstrate that label inventory is controlled in a manner that prevents confusion between similar products or revisions. Weak storage controls can undermine otherwise well-designed labeling systems.

During production, manufacturers must ensure the correct labeling is applied to the correct device. Labeling operations should include safeguards that reduce human error and prevent cross-contamination between product lines.

Reconciliation procedures are commonly used to confirm that the number of labels issued matches the number applied. Any discrepancies must be investigated and documented.

Where automated printing or barcode generation systems are used, verification steps should confirm data accuracy and print quality. Controls over in-house printing are particularly important, as uncontrolled printing systems can introduce version or data errors.

FDA evaluates whether labeling operations are integrated into overall production controls and whether documented procedures are consistently followed.

When control numbers are required, manufacturers must establish procedures to ensure they are assigned and recorded accurately. Control numbers link individual units or production lots to manufacturing records and distribution data.

Proper traceability enables effective recalls and post-market investigations. Inadequate control number management can delay corrective actions and increase regulatory risk.

The regulation requires that control numbers be documented in a manner that supports traceability to finished devices and associated records. Strong control number systems are essential for inspection readiness and risk mitigation.

Labeling controls are closely tied to Device History Record requirements under 21 CFR 820.184. The Device History Record must demonstrate that each unit or lot was manufactured in accordance with the Device Master Record.

Labeling documentation within the DHR typically includes copies or references to labeling used, control numbers applied, and inspection or verification records.

If labeling approval, inspection, or reconciliation activities are not documented within the DHR, FDA may determine that the manufacturer lacks objective evidence of compliance. Proper integration of labeling controls into recordkeeping systems is therefore critical.

FDA inspections frequently identify deficiencies in labeling control procedures. Common observations include failure to establish written procedures, inadequate documentation of label approval, poor segregation of obsolete labels, and lack of reconciliation between issued and applied labels.

In some cases, manufacturers fail to control electronic labeling systems or barcode generation software, leading to version discrepancies or inaccurate data encoding.

Because labeling directly affects device identification and patient safety, FDA treats violations in this area seriously. Repeated deficiencies may result in warning letters or enforcement actions.

Routine internal audits and cross-functional review of labeling operations are effective strategies for identifying vulnerabilities before inspection.

Although Section 820.120 predates the Unique Device Identification system, its requirements now extend to UDI implementation and modern barcode technologies.

Manufacturers must ensure that Device Identifiers and Production Identifiers are accurate, that barcodes are properly formatted, and that revisions align with regulatory database submissions. Labeling controls must address both physical durability and digital data integrity.

Modern labeling systems often incorporate automated printing, serialization software, and integrated ERP platforms. These systems must be validated and controlled under the broader quality system framework to ensure compliance with 820.120.

As labeling technologies evolve, coordination between regulatory, quality, IT, and operations teams becomes increasingly important.

For a more detailed overview, see our supporting resource on UDI Compliance for Medical Device Labels.

For a more detailed overview, see our supporting resource on FDA Medical Device Labeling Requirements.

Compliance with 21 CFR 820.120 requires durable materials, controlled production processes, and traceability support. GMP Labeling partners with medical device manufacturers to strengthen labeling systems through validated materials, barcode-ready and UDI-capable designs, and production workflows that align with regulatory expectations.

By supporting labeling durability, version control, and operational reliability, GMP Labeling helps manufacturers reduce risk associated with mix-ups, legibility failures, and traceability gaps.

For organizations preparing for inspection or evaluating their quality systems, strengthening labeling controls under 21 CFR 820.120 is a critical step toward long-term compliance and operational stability.

Even experienced manufacturers have questions about FDA medical device labeling requirements. For answers to common questions, explore our comprehensive Medical Device Labeling FAQ Page for detailed guidance on staying compliant with FDA labeling regulations.